Arch Therapeutics Inc. | Balance Sheet

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
557.30
833.50
3,960.10
5,036.50
5,994.10
4,667.40
Other Current Assets
1,019.60
43.50
42.90
107.80
85.30
151.80
Total Current Assets
1,576.90
877.00
4,003.00
5,144.30
6,079.40
4,819.20
Net Property, Plant & Equipment
0.30
-
-
-
7.20
17.30
Other Assets
10.10
-
-
-
3.50
3.50
Total Assets
1,587.30
877.00
4,003.00
5,144.30
6,090.10
4,840
ST Debt & Current Portion LT Debt
-
-
808.80
899.60
-
Other Current Liabilities
455.60
2,723.70
477.20
979.20
433.50
Total Current Liabilities
455.60
2,723.70
1,286.10
1,878.80
433.50
Long-Term Debt
944.70
955.80
966.80
78.30
-
Other Liabilities
-
4,090.00
210.00
26.20
3,430.00
Total Liabilities
1,400.30
7,769.40
2,462.90
1,983.30
3,863.60
Common Equity (Total)
187.00
6,892.40
1,540.10
3,161.00
2,226.50
Total Shareholders' Equity
187.00
6,892.40
1,540.10
3,161.00
2,226.50
Total Equity
187.00
6,892.40
1,540.10
3,161.00
2,226.50
Liabilities & Shareholders' Equity
1,587.30
877.00
4,003.00
5,144.30
6,090.10

About Arch Therapeutics

View Profile
Address
235 Walnut Street
Framingham Massachusetts 01702
United States
Employees -
Website http://www.archtherapeutics.com
Updated 07/08/2019
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development of novel approach to stop bleeding, control leaking, and manage wounds during surgery, trauma, and interventional care. Its products candidates include AC5 Devices. The company was founded by Rutledge Ellis-Behnke and Terrence W.